POINT Financial Statements From 2010 to 2026
Analyzing historical trends in various income statement and balance sheet accounts from POINT Biopharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting POINT Biopharma's valuation are summarized below:POINT Biopharma Global does not now have any trending fundamental ratios for analysis.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Check POINT Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among POINT Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . POINT financial statements analysis is a perfect complement when working with POINT Biopharma Valuation or Volatility modules.
POINT |
POINT Biopharma Global Company Return On Equity Analysis
POINT Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current POINT Biopharma Return On Equity | 0.26 |
Most of POINT Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, POINT Biopharma Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, POINT Biopharma Global has a Return On Equity of 0.2633. This is 101.1% lower than that of the Biotechnology sector and 100.72% lower than that of the Health Care industry. The return on equity for all United States stocks is 184.94% lower than that of the firm.
POINT Biopharma Global Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining POINT Biopharma's current stock value. Our valuation model uses many indicators to compare POINT Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across POINT Biopharma competition to find correlations between indicators driving POINT Biopharma's intrinsic value. More Info.POINT Biopharma Global is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for POINT Biopharma Global is roughly 1.57 . Comparative valuation analysis is a catch-all technique that is used if you cannot value POINT Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |